ZYVERSA THERAPEUTICS, INC. Depreciation
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Depreciation of $6.93 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. depreciation for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. depreciation for the quarter ending 2024-09-30 was $1.73K, a 33.35% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. depreciation for the quarter ending 2024-06-30 was $2.60K, a 0.00% change year-over-year.
- ZYVERSA THERAPEUTICS, INC. depreciation for the quarter ending 2024-03-31 was $2.60K, a 0.00% change year-over-year.
- ZYVERSA THERAPEUTICS, INC. depreciation for fiscal 2024 was $6.93K, a 33.34% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. depreciation for fiscal 2023 was $10.40K.
| Period end | Depreciation 1 month | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 11 month | Depreciation 11 month as first filed | Depreciation 12 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.73K derived: sum of 2 quarters · filed 2026-03-31 | $4.33K derived: sum of 3 quarters · filed 2026-03-31 | $6.93K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $1.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $4.33K derived: sum of 2 quarters · filed 2025-11-19 | $6.93K 10-Q · filed 2025-11-19 | $9.53K derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $2.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $5.20K 10-Q · filed 2025-08-13 | $7.80K derived: sum of 3 quarters · filed 2025-08-13 | $10.40K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $2.60K 10-Q · filed 2025-05-12 | $5.20K derived: sum of 2 quarters · filed 2025-05-12 | $7.80K derived: sum of 3 quarters · filed 2025-05-12 | $10.40K derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $2.60K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.20K derived: sum of 2 quarters · filed 2025-03-27 | $7.80K derived: sum of 3 quarters · filed 2025-03-27 | $10.40K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $2.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.20K derived: sum of 2 quarters · filed 2024-11-14 | $7.80K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $2.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $5.20K 10-Q · filed 2024-08-09 | |||||
| 2023-03-31 | $2.60K 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | $532.00 10-K · filed 2024-03-25 | ||||||
| 2022-12-12 | $9.87K 10-K · filed 2024-03-25 | $9.87K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |